PT  - JOURNAL ARTICLE
AU  - MARKUS BRUNS-TOEPLER
AU  - PHILIP HARDT
TI  - Evaluation of a New Technique for iFOBT Utilising a New Sample Collection Device with Increased Buffer Stability
DP  - 2017 Jul 01
TA  - Anticancer Research
PG  - 3735--3740
VI  - 37
IP  - 7
4099  - http://ar.iiarjournals.org/content/37/7/3735.short
4100  - http://ar.iiarjournals.org/content/37/7/3735.full
SO  - Anticancer Res2017 Jul 01; 37
AB  - Aims: The aims of the present study were: (i) Evaluate specificity and sensitivity of Hb Smart enzyme-linked immunosorbent assay (ELISA) (ScheBo Biotech) compared to colonoscopy results and (ii) assess stability of a new sample collection device containing a newly formulated buffer to extract haemoglobin using buffer and stool samples spiked with defined concentrations of haemoglobin. Materials and Methods: Stool samples were quantified with the ELISA method. The stability of haemoglobin in the extraction buffer and in native stool samples, respectively, was determined daily by ELISA during storage for 5 days at 4°C and at room temperature after addition of haemoglobin. Results: Haemoglobin ELISA had a sensitivity of 78.4% for detection of CRC with a specificity of 98%. Haemoglobin extracted in corresponding extraction buffer demonstrated stability throughout storage for 5 days at 4°C and at room temperature. Conclusion: Hb Smart represents a very promising tool for large-scale screening of CRC with regard to sample handling, stability and analysis of haemoglobin in faeces.